Home Latest Articles
Latest Articles
  • Jiang LUO, Yanping JIANG, Jian WANG, Huiyi LI, Wenzhe WU
    Chinese Journal of Pharmaceuticals. 2025, 56(11): 1433-1438.

    In order to formulate the pharmacopoeia standard of ambroxol hydrochloride inhalation solution, the key indicators of this product, including related substances, delivery characteristics, pH value, and osmolarity, were studied by referring to standards of four domestic enterprises. The methods for quality standard were optimized and verified according to the test results. The general methods and limits for accurately determining relevant substances, delivery characteristics, pH value, and osmolarity were ultimately established. This method was used to test and verify products from various manufacturers, and all results showed compliance. The newly established standards shall not be lower than the requirements of Pharmacopoeia of the People’s Republic of China for inhalation solutions and ambroxol hydrochloride injection, and can be used for quality control of ambroxol hydrochloride inhalation solutions from various manufacturers.

  • Runli ZHANG, Ganggang WANG, Fengjiao REN, Sijin WANG, Shihong MA
    Chinese Journal of Pharmaceuticals. 2025, 56(11): 1439-1446.

    Pharmaceutical water samples from various sources were collected, and 18 strains of microorganisms were isolated and purified from the samples. These 18 strains were identified by 16S rDNA sequencing, and their growth curves were analyzed. The results showed that most of the strains from pharmaceutical water system (except Cellulosimicrobium) grew well in R2A medium with a short lag phase, and a specialized microbial bank was successfully constructed. For the 18 strains in this specialized microbial bank, the minimum detection concentration range of the amplified ATP bioluminescence-based rapid detection technology was 10 - 1.0×104 cfu/mL, while for common Gram-negative bacteria in water systems, the range was 10 - 1.0×103 cfu/mL. After pre-culture based on the characteristics of the strains, most test strains showed “positive” or “overload” results under the corresponding pre-culture system and time conditions.

  • Jianfu WU, Hui KE, Xinghua PAN, Zhiyong LUO, Muyun LIU
    Chinese Journal of Pharmaceuticals. 2025, 56(11): 1447-1452.

    This study developed proficiency testing samples for microbiological safety assessments of mesenchymal stem cells (MSCs), focusing on bacterial endotoxin detection, sterility testing, and mycoplasma detection, and evaluated the effectiveness of inter-laboratory comparisons. Non-interfering raw materials were screened and processed, followed by homogeneity and stability validation. These samples were distributed to nine testing laboratories nationwide. Stability experiments revealed that under 2 - 8 ℃ storage, bacterial endotoxin- and mycoplasma-positive samples maintained detectable validity for 7 d, while sterility-positive samples remained stable for 21 d. At 35 ℃, sterility samples retained a 21-day detection window, and mycoplasma samples stored at –20 ℃ showed stability for 21 days.Inter-laboratory comparison results indicated variability in qualification rates across testing items: bacterial endotoxin and mycoplasma detection achieved 100% compliance, whereas sterility testing showed deviations with a 94.4% qualification rate. In summary, the constructed validation samples effectively supported laboratory competency evaluation in microbiological safety testing, and provide a standardized technical framework for quality control in stem cell applications.

  • Ming LING, Yanjie JIANG, Yinger QIU, Ke YING, Zhengyang FU
    Chinese Journal of Pharmaceuticals. 2025, 56(11): 1453-1458.

    The study aims to develop a rapid detection method for environmental microorganisms in pharmaceutical production by gene membrane chip technology to improve the efficiency of drug production quality supervision. Seven typical microorganisms of pharmaceutical production environment, including Bacillus cereus, Micrococcus luteus, Staphylococcus epidermidis, Staphylococcus warneri, Staphylococcus aureus, Escherichia coli and Bacillus subtilis were selected. Specific primers and probes were designed for each microorganism, and synchronous nucleic acid detection and result analysis were achieved by combining gene membrane chip with multiplex PCR technology. The method exhibits excellent specificity and stability, with a detection sensitivity of 1.0×105 copies/mL, and is suitable for routine monitoring of common microorganisms in the pharmaceutical production environment. The established seven-in-one inspection technology has advantages of simple operation, low cost and high automation, which can not only provide real-time monitoring for quality safety of drug production process, but also offer efficient technical support for government regulatory departments.

  • Xiaolong WANG, Min SHI, Rongwei LIAN, Zhikui DONG, Ruwei WANG
    Chinese Journal of Pharmaceuticals. 2025, 56(11): 1459-1463.

    To identify the structure and trace the source of an unknown impurity with a content slightly greater than 0.05% in low-density polyethylene packaged drugs. Using levosalbuterol hydrochloride nebuliser solution as the model drug, the unknown target impurity was separated and purified via preparative HPLC, and its structure was confirmed by high-resolution mass spectrometry, nuclear magnetic resonance, infrared spectroscopy. The results showed that the unknown impurity was phenylmethanol, which was originated from glue components in the product label rather than a degradation product of the drug itself. It could be classified as a general impurity with no new high-toxicity structure. This study provides a reference for the identification of unknown impurities in low-density polyethylene packaged drugs and quality control of similar products.

  • Junwei MA, Yonghui LIU, Lianjie REN
    Chinese Journal of Pharmaceuticals. 2025, 56(11): 1464-1470.
  • Baomei ZHANG, Junyong LUO, Tingting WEI, Jie TIAN
    Chinese Journal of Pharmaceuticals. 2025, 56(11): 1471-1474.
  • Xiao YUAN, Yi LIANG
    Chinese Journal of Pharmaceuticals. 2025, 56(11): 1475-1479.
  • Haonan ZHANG, Gexia GENG, Liping LI, Yaoyao WANG, Xiaopeng LI
    Chinese Journal of Pharmaceuticals. 2025, 56(11): 1480-1485.
  • Lili ZHAO, Yuqiang ZHU, Peng LI, Zhongsong ZHU, Zhong LIU
    Chinese Journal of Pharmaceuticals. 2025, 56(10): 1243-1251.

    Antibody-drug conjugates(ADCs) are novel antineoplastics that combine the high targeting specificity of monoclonal antibodies with the potent cytotoxicity of small-molecule toxins. By selectively delivering cytotoxic payloads to tumor cells, ADCs achieve effective tumor cell killing while minimizing damage to healthy cells and reducing systemic toxicity. These innovative agents, often referred to as “biological missile”, are leading a new era in targeted cancer therapy.Although three generations of ADCs have been applied to cancer treatment, further optimization of the components of ADCs is still required to address challenges such as stability, cytotoxicity, and drug resistance. This article summarizes the approved ADCs and those under clinical research, outlines innovative directions for next-generation ADCs, to provide insights for advancing research and development of novel cancer treatments using ADC technology.

News